# Bausch Health Companies Inc. (BHC) fundamentals

Data as of 2026-11-04. NYSE, United States. Sector: Healthcare / Pharmaceuticals. Price $8.14, market value $3.0 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Bausch Health Companies Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **PEG: 0.00**. A PEG of 0.00 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 0.3×**. Each dollar of revenue is priced at 0.3×, a low multiple typical of thin-margin businesses or out-of-favour stocks.
- **EV / EBITDA: 5.6×**. Enterprise value is 5.6× operating earnings before depreciation, the multiple that ignores how the company is financed; below 8× is inexpensive for most sectors.
- **Free-cash-flow yield: 60.0%** (5-yr avg 14.7%). Free cash flow equals 60.0% of the market value, above its five-year average of 14.7%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.

## Profitability
- **Gross margin: 68.3%**. Bausch Health Companies Inc. keeps 68.3% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 27.2%**. 27.2% of revenue is left after running the business, an exceptional level.
- **Net margin: 1.5%**. 1.5% of each dollar of sales reaches the bottom line.
- **Return on equity: -28.9%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 15.6%**. Return on all capital, debt included, is 15.6%: comfortably above what that capital costs.
- **Return on assets: -3.1%**. Each dollar of assets produces -3.1% of profit.

## Growth
- **Revenue growth (1 yr): 8.5%** (3-yr 8.7%/yr, 5-yr 5.4%/yr). Revenue grew 8.5% over the last year, against 5.4% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 458.3%**. Earnings per share rose 458.3%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Net debt / EBITDA: 4.8×**. It would take 4.8 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Interest coverage: 1.9×**. Operating profit covers interest 1.9×, thin but manageable.
- **Current ratio: 1.47** (quick 1.08). Current assets cover the next year's liabilities 1.47 times.
- **Altman Z-score: 0.81**. A Z-score of 0.81 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Bausch Health Companies Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: hold** (5 analysts). 5 analysts cover Bausch Health Companies Inc.; the consensus is hold, with an average price target of $7.70 (-5% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 14.2%** (YTD 15.4%, 3-mo 14.6%). The shares are up 14.2% over twelve months including dividends.
- **From 52-week high: -10.0%** (88.0% above the low). Trading 10% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 69**. An RSI of 69 is neutral.
- **Beta (1 yr): 0.93** (volatility 63%). Beta of 0.93 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=BHC · Page: https://foliofundamentals.com/stocks/bhc

Not investment advice.